In the second part of a 2-part series, Rana R. McKay, MD, associate professor of Medicine and Urology, Moores Cancer Center, University of California San Diego, discusses second-line treatment options ...
RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced results from the Phase 3 LITESPARK-012 trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results